Features | Partner Sites | Information | LinkXpress
Sign In
SIEMENS DIAGNOSTICS

Molecular Blood Test Detects Colorectal Cancer

By Labmedica International staff writers
Posted on 26 Feb 2013
A molecular blood test that identifies changes in DNA associated with colorectal cancer is now available in the United States.

The test is designed to aid the detection of colorectal cancer, the third leading cause of cancer-related deaths, but only 40% of cases are diagnosed in early stages, due to low screening rates.

The new test is based on DNA methylation of the Septin9 gene, a proprietary biomarker associated with colorectal cancer that was identified by Epigenomics AG (Frankfurt, Germany). Epigenomics has demonstrated in more than a half dozen peer-reviewed studies involving approximately 3,000 specimens of patients with diagnosed colorectal cancer and of healthy control subjects that methylated Septin9 in blood plasma indicates an increased likelihood of colorectal cancer.

Epigenomics is sponsoring a multicenter clinical study named PRESEPT in collaboration with Quest Diagnostics (Madison, NJ, USA) and other organizations to evaluate the Septin9 biomarker's performance for colorectal cancer screening in screening-guideline-eligible individuals who have not been diagnosed with colorectal cancer. Quest Diagnostics is the first commercial laboratory in the USA to offer a laboratory-developed test based on the Septin9 biomarker.

Jon R. Cohen, MD senior vice president and chief medical officer of Quest Diagnostics said, "Early detection rates are dismally low, largely because many patients find existing tests and procedures invasive or unpleasant. Our ColoVantage colorectal cancer test, which is based on Septin9, has yet to be clinically validated as a screening test. Rather, it may promote further evaluation in patients who have resisted testing in the past or as an adjunct to existing procedures." ColoVantage was validated in multiple studies and achieved an overall 70% sensitivity and 89% specificity. ColoVantage has successfully detected cancer at all stages. Patients who test positive for methylated Septin9 should be further evaluated for the presence of colorectal cancer.

Related Links:
Epigenomics AG
Quest Diagnostics


comments powered by Disqus

Channels

Clinical Chemistry

view channel
Image: The Cobas 6000 Multipurpose Clinical Laboratory analyzer (Photo courtesy of Roche Diagnostics).

Low Density Lipoprotein Apolipoprotein-B Assay Validated

The relationship between apolipoprotein-B (Apo-B) concentration and the risk of developing cardiovascular disease (CVD) is more robust than the relationship between low density lipoprotein cholesterol... Read more

Genetic Tests

view channel
Histopathology of colonic adenocarcinoma; the glands are enlarged and filled with necrotic debris (Photo courtesy of the University of Utah).

Promising Blood Biomarkers Isolated for Colorectal Cancer

The search for blood-borne biomarkers that could be used to screen for colorectal cancer (CRC) has uncovered two promising candidates that may one day lead to the development of a simple blood test.... Read more

Microbiology

view channel
Image: IC 3D technology rapidly detects bacterial infection in blood samples (Photo courtesy of University of California, Irvine).

DNA-Based Droplet System Rapidly Detects Bacterial Infection in the Bloodstream

A new test for bacterial infection in the bloodstream is based on an innovative DNA labeling and particle counting system. Investigators at the University of California, Irvine (USA) recently described... Read more

Industry News

view channel

Collaboration to Bring Personalized Cancer Care to Singapore

A German company specializing in cancer diagnosis will be extending its expertise in personalized care to the health care market in Singapore. New Oncology (Cologne, Germany) announced recently that it has entered into a collaboration agreement with the National Cancer Centre Singapore (Singapore). New Oncology will... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.